Completed PHASE4 INTERVENTIONAL 1-arm NCT00934713

The Effect of Montelukast Treatment in Wheezy Infants (Montelukast)

The Effect of Montelukast Therapy on Respiratory Symptoms, Lung Function and Airway Responsiveness in Wheezy Very Young Children

Sponsor: Merck Sharp & Dohme LLC

Conditions Lung Disease, Obstructive Signs and Symptoms, Respiratory

Interventions montelukast

Updated 6 times since 2017 Last updated: Jul 7, 2009 Started: Sep 30, 2004 Primary completion: Apr 30, 2008 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Lung Disease, Obstructive and Signs and Symptoms, Respiratory and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jun 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jun 2022 [monthly]

Completed PHASE4
Apr 2020 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Apr 2020 [monthly]

Completed PHASE4

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
University of Helsinki

Data source: University of Helsinki

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Helsinki, Finland